Novacyt's Primerdesign division signs USD3m diagnostics supply agreement with Genesis Diagnostics
27 November 2018 -

Novacyt SA (Paris:ALNOV) (AIM: NCYT), a specialist in clinical diagnostics, announced on Monday the signing by its molecular testing division, Primerdesign Ltd, of an exclusive supply agreement worth a minimum of USD3m with Genesis Diagnostics.

Genesis Diagnostics is a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease and personalised medicine.

Under this supply agreement, Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women's health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.

Also, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years.

Reportedly, the supply of products under the agreement is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of USD600,000 per year.